200 Mass Tort Liens Waived for Maine Medicaid Clients
A big victory was secured for Maine Medicaid claimants in the Mallinckrodt litigation. MASSIVE's Mass Tort team met with Maine Medicaid to discuss the scope of the project and proposed terms. MASSIVE convinced Maine Medicaid the workload would not match its recovery. Maine Medicaid agreed to waive its rights to recovery.
"Mallinckrodt Opioids is a huge case and it's imperative to keep our clients at the forefront of the conversations with lien holders" said Megan Stewart, Mass Tort Lien Resolution Liaison at MASSIVE. "Our long-standing relationships with lien holders allow us to ensure that all rights are protected, and claimants can get the most out of their settlements. Meeting with Maine Medicaid early allowed us to lay out the parameters of the project and obtain a full waiver for claimants, without compromising their Medicaid coverage in the future."
"For a high-volume project like Mallinckrodt, it's important to ensure that processes are in place before the work begins to ensure the project runs smoothly" said
This is a success for the almost 200 clients from
MASSIVE is proud to bring some justice to those who suffered through the opioid epidemic. More information about the Mallinckrodt lien resolution process can be found on MASSIVE's website.
MASSIVE is a nationwide provider of healthcare lien resolution services. By partnering with personal injury law firms across in both Single Event and Mass Tort cases, MASSIVE expedites settlements through cutting edge software, services, and support.
View original content to download multimedia:https://www.prnewswire.com/news-releases/200-mass-tort-liens-waived-for-maine-medicaid-clients-301797179.html
SOURCE MASSIVE: Medical & Subrogation Specialists
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baidu Announces Dual-Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited
- Supremo Announces Availability of Shopify Inventory Management App Following June 2026 Launch
- Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
BankruptcySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share